Results 131 to 140 of about 756,852 (217)

Grace Face Sign in Generalized Myasthenia Gravis (MG)

Neurology India, 2023
Reshma S, Shaik, Sandhya, Manorenj
openaire   +3 more sources

Targeting BLyS and APRIL with Telitacicept versus Conventional Immunotherapy in Generalized Myasthenia Gravis: A Comparative Study. [PDF]

Immunotargets Ther
Yang Y, Kang N, Zhu Y, Ma C, Zhu R.
europepmc   +1 more source

Incremental health care resource utilization, costs, and predictors of high costs in generalized myasthenia gravis. [PDF]

J Manag Care Spec Pharm
Grover K, Gandhi K, Boonmak P, Cloutier M, Coteur G, Zhdanava M, Tardif-Samson A, El Khoury AC, Wang Y, Choudhry Z, Silvestri NJ.   +10 more
europepmc   +1 more source

Digital Monitoring of Patients with Generalized Myasthenia Gravis: A Prospective Pilot Study. [PDF]

Neurol Ther
Vesperinas A, Rocaspana-Codana J, Reyes-Leiva D, Caballero-Ávila M, Carbayo Á, Collet-Vidiella R, Llansó L, Gallardo E, Turon-Sans J, Rojas-García R, Cortés-Vicente E.   +10 more
europepmc   +1 more source

Rapid Onset of Clinical Response to Eculizumab in a Single-Center Cohort of Older Patients with Refractory Generalized Myasthenia Gravis. [PDF]

NeuroSci
D'Alvano G, Del Giudice S, D'Anna F, Todisco V, Tessitore A, Bisecco A.   +5 more
europepmc   +1 more source

Bulbar Onset Generalized Myasthenia Gravis in an Elderly Patient: A Diagnostic Challenge. [PDF]

Cureus
Abay B, Mehjeba M, Bajgamage A, Suman S.
europepmc   +1 more source

Multidomain Fatigue, Cognitive, and Quality of Life Observations in Generalized Myasthenia Gravis Under Ravulizumab: A Case Series. [PDF]

Neurol Ther
Zanghì A, Di Filippo PS, Rutigliano C, Avolio C, D'Amico E.   +4 more
europepmc   +1 more source

Efficacy and Safety of Gefurulimab in Generalized Myasthenia Gravis: The PREVAIL Phase 3 Randomized Clinical Trial.

JAMA Neurol
Gwathmey KG, Saccà F, Howard JF, Vu T, Xi J, Mäurer M, Ruck T, Shin HY, Takahashi MP, Casasnovas C, Smilowski M, Peric S, Masuda M, Scholz J, Shang S, Yee M, Rakhade S, Annane D.   +17 more
europepmc   +1 more source

A Delphi consensus on integrating novel therapies into the management of generalized myasthenia gravis. [PDF]

Ther Adv Neurol Disord
Vissing J, Zimprich F, Atula S, Chan A, Andersen H, Topakian R, Tannemaat MR, Weber KP, Cetin H, Neuwirth C, Kuusisto H, Loescher WN.   +11 more
europepmc   +1 more source

The Fiscal Consequences for the Canadian Government of Efgartigimod in the Treatment of Generalized Myasthenia Gravis. [PDF]

J Health Econ Outcomes Res
Paquete AT, Connolly MP, Qi C, Katzberg H, Raza S, Kassardjian C, Siddiqi ZA, Kaprielian R, Locklin J, Phillips GA, Kotsopoulos N.   +10 more
europepmc   +1 more source